Withdrawal of Kirkland & Ellis from Novartis Antitrust Case amid Conflict of Interest Claims

In a significant legal development, a New York federal judge has accepted the withdrawal of the entire Kirkland & Ellis LLP team from Novartis Pharma’s legal defense against antitrust allegations concerning the eye medication Eylea. This decision follows a motion by Regeneron Pharmaceuticals, the plaintiff, seeking the disqualification of Kirkland & Ellis due to an alleged “unthinkable” conflict of interest, as the firm had previously represented Regeneron. For more details, please visit the full report on Law360.